



For Immediate Release | Global Communications | MetLife, Inc.

MetLife Announces 3Q 2025 Results

- Net income was \$818 million, or \$1.22 per share.
- Adjusted earnings increased 15%¹ to \$1.6 billion, primarily driven by higher variable investment income and volume growth.
- Adjusted earnings per share, excluding total notable items, up 21% to \$2.34.
- Premiums, fees and other revenues (PFOs) were \$12.5 billion.
- Adjusted PFOs, excluding pension risk transfers (PRT), up 4% to \$12.5 billion, with growth in all segments except MetLife Holdings.
- Net investment income up 16% to \$6.1 billion.
- Variable investment income was \$483 million, primarily reflecting higher private equity returns.
- Book value per share (BVPS) up 1% to \$39.52. Adjusted BVPS increased 3% to \$56.57.
- Returned approximately \$875 million to shareholders via share repurchases and common stock dividends.
- Holding company cash and liquid assets totaled \$4.9 billion at quarter end.
- Delivered solid Group Benefits underwriting, including a 230-basis point sequential improvement in non-medical health loss ratio.
- Secured \$12 billion in PRT mandates in the fourth quarter to-date.
- Grew Asia sales 34% on a constant currency basis, with Japan up 31%, reflecting new retirement-oriented products. Other Asia sales grew 39% on a constant currency basis.
- Expanded MetLife Xcelerator in Latin America through a new partnership with Mercado Libre in Brazil and Mexico.

Earnings Per Share

3Q 2025

Net Income	\$1.22
Adjusted Earnings	\$2.37

Return on Equity (ROE)

3Q 2025

ROE	13.1%
Adjusted ROE	16.9%

Comment from Michel Khalaf, President and Chief Executive Officer:

MetLife delivered an excellent third quarter that reinforces the strength of our diversified business model and disciplined execution of our New Frontier strategy.

Adjusted earnings per share, excluding total notable items, grew 21% year-over-year, driven by strong variable investment income, broad-based volume growth, and diligent expense management.

Momentum continues to build as we head into year-end. We've secured \$12 billion in PRT mandates in the fourth quarter to-date and launched strategic partnerships that will expand our reach and enhance access to our insurance and retirement solutions.

These results demonstrate MetLife's earnings power and our ability to deliver all-weather performance – driving responsible growth and high returns for shareholders today and in the future.

¹In this news release, all comparisons of results for the third quarter of 2025 are with the third quarter of 2024, unless otherwise noted.

Third Quarter 2025 Summary

(\$ in millions, except per share data)	Three Months Ended September 30,		
	2025	2024	Change
Premiums, fees and other revenues	\$ 12,526	\$ 12,523	
Net investment income	6,089	5,227	16%
Net investment gains (losses)	(325)	(77)	
Net derivative gains (losses)	(929)	767	
Total revenues	\$ 17,361	\$ 18,440	
Adjusted premiums, fees and other revenues	\$ 12,461	\$ 12,471	
Adjusted premiums, fees and other revenues, excluding pension risk transfers (PRT)	\$ 12,471	\$ 11,942	4%
Market risk benefit remeasurement gains (losses)	\$ 263	\$ (531)	
Net income (loss)	\$ 818	\$ 1,275	(36)%
Net income (loss) per share	\$ 1.22	\$ 1.81	(33)%
Adjusted earnings	\$ 1,584	\$ 1,375	15%
Adjusted earnings per share	\$ 2.37	\$ 1.95	22%
Adjusted earnings, excluding total notable items	\$ 1,566	\$ 1,359	15%
Adjusted earnings, excluding total notable items per share	\$ 2.34	\$ 1.93	21%
Book value per share	\$ 39.52	\$ 39.02	1%
Adjusted book value per share	\$ 56.57	\$ 54.72	3%
Expense ratio	21.7%	19.9%	
Direct expense ratio, excluding total notable items related to direct expenses and PRT	11.6%	11.7%	
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT	19.8%	20.7%	
ROE	13.1%	20.2%	
Adjusted ROE	16.9%	14.6%	
Adjusted ROE, excluding total notable items	16.7%	14.4%	

Information regarding the non-GAAP and other financial measures included in this news release and reconciliation of the non-GAAP financial measures to GAAP measures are in "Non-GAAP and Other Financial Disclosures" below and in the tables that accompany this news release.

In this news release, all comparisons of results for the third quarter of 2025 are with the third quarter of 2024, unless otherwise noted.

Supplemental slides for the third quarter of 2025, titled "3Q25 Supplemental Slides" are available on the MetLife Investor Relations website at <https://investor.metlife.com> and in the Form 8-K furnished by MetLife to the U.S. Securities and Exchange Commission in connection with this earnings release. Supplemental information about MetLife's diversified global investment portfolio is contained in the "3Q25 - General Account Assets Under Management Fact Sheet," available on the above-mentioned website.

Total Company Discussion

MetLife reported third quarter 2025 premiums, fees and other revenues of \$12.5 billion, flat compared with the prior year quarter. Adjusted premiums, fees and other revenues, excluding pension risk transfers, were \$12.5 billion, up 4 percent.

Net investment income was \$6.1 billion, up 16 percent, primarily due to increases in the estimated fair value of certain securities that do not qualify as separate accounts under GAAP. Adjusted net investment income was \$5.4 billion, up 6 percent, primarily reflecting higher returns on private equity assets.

Net investment losses were \$325 million, or \$257 million after tax, reflecting normal trading activity and a stable credit environment. Net derivative losses amounted to \$929 million, or \$734 million after tax, due to stronger equity markets, higher long-term interest rates, and strengthening of the U.S. dollar.

Net income decreased 36 percent to \$818 million. Higher net derivative losses and net investment losses were the primary drivers, partially offset by market risk benefit remeasurement gains and higher adjusted earnings. On a per-share basis, net income decreased 33 percent to \$1.22.

Adjusted earnings were \$1.6 billion, up 15 percent on both a reported basis and a constant currency basis. On a per-share basis, adjusted earnings were \$2.37, up 22 percent.

THIRD QUARTER 2025 NOTABLE ITEMS

(\$ in millions)	Adjusted Earnings							
	Three Months Ended September 30, 2025							
Notable Items	Group Benefits	RIS	Asia	Latin America	EMEA	MetLife Holdings	Corporate & Other	Total
Actuarial assumption review and other insurance adjustments	\$(2)	\$13	\$70	\$(4)	\$(1)	\$13	\$0	\$89
Tax adjustments	—	—	—	(71)	—	—	—	(71)
Total notable items	\$(2)	\$13	\$70	\$(75)	\$(1)	\$13	\$0	\$18

Annual Actuarial Assumption Review and Other Insurance Adjustments

In the third quarter of 2025, MetLife performed its annual global actuarial assumption review. The actuarial assumption review and other insurance adjustments during the quarter positively impacted net income by \$102 million and adjusted earnings by \$89 million.

Tax Adjustments

The company recorded a \$71 million after-tax charge in the third quarter related to the resolution of an industry-wide tax matter in Mexico regarding the Value-Added Tax deduction of certain health insurance claims expenses.

Adjusted Earnings by Segment Summary

Segment	Three Months Ended September 30, 2025	
	Change from prior-year period (on a reported basis)	Change from prior-year period (on a constant currency basis)
Group Benefits	22%	
Retirement and Income Solutions (RIS)	(8)%	
Asia	77%	78%
Latin America	(33)%	(34)%
Europe, the Middle East and Africa (EMEA)	26%	24%
MetLife Holdings	12%	

Business Discussions

GROUP BENEFITS

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change
Adjusted earnings	\$455	\$373	22%
Notable item(s)	\$(2)	\$(58)	
Adjusted earnings ex. notables	\$457	\$431	6%
Adjusted PFOs	\$6,306	\$6,146	3%

- **Adjusted earnings** were \$455 million, up 22 percent, primarily due to the impact of the actuarial assumption review and other insurance adjustments in the prior-year period.
- **Excluding notable items, adjusted earnings** were \$457 million, up 6 percent, reflecting favorable expense margins and volume growth, partially offset by less favorable life underwriting.
- **Adjusted PFOs** were \$6.3 billion, up 3 percent, driven by core and voluntary products, partially offset by the impact of favorable mortality on participating life contracts. PFOs from participating life contracts can fluctuate with claims experience.

RIS

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change
Adjusted earnings	\$436	\$472	(8)%
Notable item(s)	\$13	\$104	
Adjusted earnings ex. notables	\$423	\$368	15%
Adjusted PFOs	\$1,186	\$1,579	(25)%
Adjusted PFOs, excluding PRT	\$1,196	\$1,050	14%

- **Adjusted earnings** were \$436 million, down 8 percent, reflecting the impact of the prior-year actuarial assumption review.
- **Excluding notable items, adjusted earnings** were \$423 million, up 15 percent, largely due to higher variable investment income.
- **Adjusted PFOs, excluding PRT**, were \$1.2 billion, up 14 percent, mainly driven by higher structured settlement and UK longevity reinsurance sales.
- **Total liability exposure** grew 3 percent, including 4 percent in general account liabilities.

ASIA

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change	Constant currency change
Adjusted earnings	\$543	\$306	77%	78%
Notable item(s)	\$70	\$(41)		
Adjusted earnings ex. notables	\$473	\$347	36%	37%
Adjusted PFOs	\$1,717	\$1,710	—%	1%
Asia general account assets under management (at amortized cost)	\$140,892	\$135,107	4%	6%

- **Adjusted earnings** were \$543 million, up 77 percent on a reported basis and up 78 percent on a constant currency basis, reflecting the impact of the annual actuarial assumption review.
- **Excluding notable items, adjusted earnings** were \$473 million, up 36 percent on a reported basis and up 37 percent on a constant currency basis, mainly driven by higher variable investment income and volume growth.
- **Adjusted PFOs** were \$1.7 billion, flat on a reported basis, and up 1 percent on a constant currency basis.
- **Asia general account assets under management (at amortized cost)** were \$140.9 billion, up 6 percent on a constant currency basis.
- **Sales** were \$786 million, up 34 percent on a constant currency basis, driven by a 31 percent increase in Japan and a 39 percent increase in Other Asia markets.

LATIN AMERICA

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change	Constant currency change
Adjusted earnings	\$147	\$221	(33)%	(34)%
Notable item(s)	\$(75)	\$4		
Adjusted earnings ex. notables	\$222	\$217	2%	2%
Adjusted PFOs	\$1,663	\$1,496	11%	11%

- **Adjusted earnings** were \$147 million, down 33 percent on a reported basis and down 34 percent on a constant currency basis, due to a value-added tax charge in Mexico.
- **Excluding notable items, adjusted earnings** were \$222 million, up 2 percent on both a reported and constant currency basis, primarily driven by volume growth across the region.
- **Adjusted PFOs** were \$1.7 billion, up 11 percent on both a reported and a constant currency basis, due to strong growth across the region.
- **Sales** were \$441 million, up 15 percent on a constant currency basis, driven by growth across the region.

EMEA

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change	Constant currency change
Adjusted earnings	\$88	\$70	26%	24%
Notable item(s)	\$(1)	\$(5)		
Adjusted earnings ex. notables	\$89	\$75	19%	17%
Adjusted PFOs	\$727	\$655	11%	9%

- **Adjusted earnings** were \$88 million, up 26 percent on a reported basis, driven by volume growth and higher recurring interest margins.
- **Excluding notable items, adjusted earnings** were \$89 million, up 19 percent on a reported basis and up 17 percent on a constant currency basis, primarily due to strong volume growth.
- **Adjusted PFOs** were \$727 million, up 11 percent on a reported basis and up 9 percent on a constant currency basis, reflecting strong growth across the region.
- **Sales** were \$301 million, up 24 percent on a constant currency basis, reflecting strong growth across most markets.

METLIFE HOLDINGS

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change
Adjusted earnings	\$203	\$182	12%
Notable item(s)	\$13	\$12	
Adjusted earnings ex. notables	\$190	\$170	12%
Adjusted PFOs	\$729	\$793	(8)%

- **Adjusted earnings** were \$203 million, up 12 percent.
- **Excluding notable items, adjusted earnings** were \$190 million, up 12 percent, primarily reflecting higher variable investment income.
- **Adjusted PFOs** were \$729 million, down 8 percent, largely due to continued run-off of the business.

CORPORATE & OTHER

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change
Adjusted earnings	\$(288)	\$(249)	

- **Adjusted loss** of \$288 million, compared to an adjusted loss of \$249 million, primarily due to elevated expenses, driven by market-related employee costs and higher interest payments on outstanding debt.

INVESTMENTS

(\$ in millions)	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Change
Adjusted net investment income	\$5,440	\$5,143	6%

- **Adjusted net investment income** was \$5.4 billion, up 6 percent. Variable investment income increased 198 percent to \$483 million, primarily driven by higher returns on private equity assets.

Contacts: For Media: Jane Slusark (347) 989-5477, Jane.Slusark@metlife.com
For Investors: John Hall (212) 578-7888, John.A.Hall@metlife.com

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

Conference Call

MetLife will hold its third quarter 2025 earnings conference call and audio webcast on Thursday, November 6, 2025, from 9-10 a.m. (ET). The conference call will be available live via the internet. To listen to the conference call, click the following link to register (<https://events.q4inc.com/attendee/817838289>).

The conference call will be available for replay via telephone and the internet beginning at 11:00 a.m. (ET) on Thursday, November 6, 2025, until Thursday, November 13, 2025, at 11:59 p.m. (ET). To listen to a replay of the conference call via telephone, dial 800-770-2030 (U.S.) or 647-362-9199 (outside the U.S.). The Conference ID for the replay is 17886 followed by the # key. To access the replay of the conference call via the internet, visit the MetLife Investor Relations webpage (<https://investor.metlife.com>).

###

Non-GAAP and Other Financial Disclosures

Any references in this news release (except in this section and the tables that accompany this release) to:

- (i) net income (loss);
- (ii) net income (loss) per share;
- (iii) adjusted earnings;
- (iv) adjusted earnings per share;
- (v) book value per share;
- (vi) adjusted book value per share;
- (vii) return on equity; and
- (viii) adjusted return on equity.

should be read as, respectively:

- (i) net income (loss) available to MetLife, Inc.'s common shareholders;
- (ii) net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share;
- (iii) adjusted earnings available to common shareholders;
- (iv) adjusted earnings available to common shareholders per diluted common share;
- (v) book value per common share;
- (vi) adjusted book value per common share;
- (vii) return on MetLife, Inc.'s common stockholders' equity; and
- (viii) adjusted return on MetLife, Inc.'s common stockholders' equity.

In this news release, MetLife presents certain measures of its performance on a consolidated and segment basis that are not calculated in accordance with accounting principles generally accepted in the United States of America (GAAP). MetLife believes that these non-GAAP financial measures enhance our investors' understanding of MetLife's performance by highlighting the results of operations and the underlying profitability drivers of the business. Segment-specific financial measures are calculated using only the portion of consolidated results attributable to that specific segment.

The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:

Non-GAAP financial measures:

- (i) total adjusted revenues;
- (ii) total adjusted expenses;
- (iii) adjusted premiums, fees and other revenues;
- (iv) adjusted premiums, fees and other revenues, excluding PRT;
- (v) adjusted net investment income;
- (vi) adjusted earnings available to common shareholders;
- (vii) adjusted earnings available to common shareholders, excluding total notable items;
- (viii) adjusted earnings available to common shareholders per diluted common share;
- (ix) adjusted earnings available to common shareholders, excluding total notable items, per diluted common share;
- (x) adjusted return on equity;
- (xi) adjusted return on equity, excluding total notable items;

Comparable GAAP financial measures:

- (i) total revenues;
- (ii) total expenses;
- (iii) premiums, fees and other revenues;
- (iv) premiums, fees and other revenues;
- (v) net investment income;
- (vi) net income (loss) available to MetLife, Inc.'s common shareholders;
- (vii) net income (loss) available to MetLife, Inc.'s common shareholders;
- (viii) net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share;
- (ix) net income (loss) available to MetLife, Inc.'s common shareholders per diluted common share;
- (x) return on equity;
- (xi) return on equity;

(xii)	investment portfolio gains (losses);	(xii)	net investment gains (losses);
(xiii)	derivative gains (losses);	(xiii)	net derivative gains (losses);
(xiv)	adjusted capitalization of deferred policy acquisition costs (DAC);	(xiv)	capitalization of DAC;
(xv)	total MetLife, Inc.'s adjusted common stockholders' equity;	(xv)	total MetLife, Inc.'s stockholders' equity;
(xvi)	total MetLife, Inc.'s adjusted common stockholders' equity, excluding total notable items;	(xvi)	total MetLife, Inc.'s stockholders' equity;
(xvii)	adjusted book value per common share;	(xvii)	book value per common share;
(xviii)	adjusted other expenses;	(xviii)	other expenses;
(xix)	adjusted other expenses, net of adjusted capitalization of DAC;	(xix)	other expenses, net of capitalization of DAC;
(xx)	adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses;	(xx)	other expenses, net of capitalization of DAC;
(xxi)	adjusted expense ratio;	(xxi)	expense ratio;
(xxii)	adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT;	(xxii)	expense ratio;
(xxiii)	direct expenses;	(xxiii)	other expenses;
(xxiv)	direct expenses, excluding total notable items related to direct expenses;	(xxiv)	other expenses;
(xxv)	direct expense ratio;	(xxv)	expense ratio;
(xxvi)	direct expense ratio, excluding total notable items related to direct expenses and PRT;	(xxvi)	expense ratio;
(xxvii)	future policy benefits at original discount rate; and	(xxvii)	future policy benefits at balance sheet discount rate; and
(xxviii)	free cash flow of all holding companies.	(xxviii)	MetLife, Inc. (parent company only) net cash provided by (used in) operating activities.

Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are not accessible on a forward-looking basis because we believe it is not possible without unreasonable effort to provide other than a range of net investment gains and losses and net derivative gains and losses, which can fluctuate significantly within or outside the range and from period to period and may have a material impact on net income.

Any of these financial measures shown on a constant currency basis reflect the impact of changes in foreign currency exchange rates and are calculated using the average foreign currency exchange rates for the current period and applied to the comparable prior period ("constant currency basis").

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings news release and in this period's quarterly financial supplement, which is available at MetLife's Investor Relations webpage (<https://investor.metlife.com>).

MetLife's definitions of non-GAAP and other financial measures discussed in this news release may differ from those used by other companies:

Adjusted earnings and related measures

- adjusted earnings;
- adjusted earnings available to common shareholders;
- adjusted earnings available to common shareholders, on a constant currency basis;
- adjusted earnings available to common shareholders, excluding total notable items;
- adjusted earnings available to common shareholders, excluding total notable items, on a constant

- currency basis;
- adjusted earnings available to common shareholders per diluted common share;
- adjusted earnings available to common shareholders, on a constant currency basis per diluted common share;
- adjusted earnings available to common shareholders, excluding total notable items per diluted common share; and
- adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis per diluted common share.

Adjusted earnings is used by MetLife's chief operating decision maker, its chief executive officer, to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is MetLife's GAAP measure of segment performance. Adjusted earnings and related measures based on adjusted earnings are also the measures by which senior management's and many other employees' performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and related measures based on adjusted earnings allow analysis of MetLife's performance relative to its business plan and facilitate comparisons to industry results.

Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.

Adjusted earnings, along with the related adjusted revenues, adjusted expenses and adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, (iii) revenues and costs related to divested businesses, and (iv) other adjustments. Also, adjusted earnings and related measures exclude results of discontinued operations under GAAP.

Market volatility can have a significant impact on MetLife's financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefit remeasurement gains (losses) and goodwill impairments. Further, net investment income is adjusted to exclude similar items relating to joint ventures accounted for under the equity method ("Joint venture adjustments"), and policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.

Asymmetrical and non-economic accounting adjustments are made in calculating adjusted earnings:

- Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment ("Investment hedge adjustments").
- Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance.
- Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.
- Policyholder liability remeasurement gains (losses) excludes asymmetrical accounting associated with in-force reinsurance.
- Interest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance.

"Divested businesses" are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to

be included in results of discontinued operations under GAAP.

Other adjustments are made in calculating adjusted earnings:

- Net investment income and interest credited to policyholder account balances exclude certain amounts related to contractholder-directed equity securities ("Unit-linked contract income" and "Unit-linked contract costs").
- Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic guaranteed interest contracts ("GICs") accounted for as freestanding derivatives.
- Net investment income and other expenses also exclude Reinsurance adjustments (as defined below).
- Other revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.
- Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.
- "Reinsurance adjustments" relate to amounts subject to ceded reinsurance arrangements with third parties and joint ventures, including (i) the related investment returns and expenses which are passed through to the reinsurers and (ii) the corresponding invested assets and cash and cash equivalents.

Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.

The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife's effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.

In addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium, which is reported as a reduction to net income (loss) available to MetLife, Inc.'s common shareholders.

Investment portfolio gains (losses) and derivative gains (losses)

These are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).

Return on equity and related measures

- Total MetLife, Inc.'s adjusted common stockholders' equity: total MetLife, Inc.'s common stockholders' equity, excluding unrealized investment gains (losses), net of related offsets, deferred gains (losses) on derivatives, future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment components of accumulated other comprehensive income (loss) ("AOCI") and the estimated fair value of certain ceded reinsurance-related embedded derivatives, all net of income tax.
- Total MetLife, Inc.'s adjusted common stockholders' equity, excluding total notable items: total MetLife, Inc.'s common stockholders' equity, excluding unrealized investment gains (losses), net of related offsets, deferred gains (losses) on derivatives, future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement

gains (losses) and defined benefit plans adjustment components of AOCI, the estimated fair value of certain ceded reinsurance-related embedded derivatives and total notable items, all net of income tax.

- Return on MetLife, Inc.'s common stockholders' equity: net income (loss) available to MetLife, Inc.'s common shareholders divided by MetLife, Inc.'s average common stockholders' equity.
- Adjusted return on MetLife, Inc.'s common stockholders' equity: adjusted earnings available to common shareholders divided by MetLife, Inc.'s average adjusted common stockholders' equity.
- Adjusted return on MetLife, Inc.'s common stockholders' equity, excluding total notable items: adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.'s average adjusted common stockholders' equity, excluding total notable items.

The above measures represent a level of equity that excludes most components of AOCI, such as unrealized investment gains (losses), net of related offsets, and future policy benefits discount rate remeasurement gains (losses), as well as the impact of certain ceded reinsurance-related embedded derivatives, as these amounts are primarily driven by market volatility.

Expense ratio, direct expense ratio, adjusted expense ratio and related measures

- Expense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.
- Direct expense ratio: direct expenses, divided by adjusted premiums, fees and other revenues. Direct expenses are comprised of employee-related costs, third-party staffing costs, and general and administrative expenses.
- Direct expense ratio, excluding total notable items related to direct expenses and PRT: direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.
- Adjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.
- Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.

Asia general account (GA) assets under management (GA AUM) and related measures

Asia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio. Asia GA AUM is stated at estimated fair value and is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale, cash and cash equivalents, and accrued investment income on such assets, and excludes policy loans, contractholder-directed equity securities, fair value option securities, mortgage loans originated for third parties, assets subject to ceded reinsurance arrangements with third parties and joint ventures, and certain other invested assets. Mortgage loans, net of mortgage loans originated for third parties ("net mortgage loans") (including commercial ("net commercial mortgage loans"), agricultural ("net agricultural mortgage loans") and residential mortgage loans) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.

Asia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on net mortgage loans (including net commercial mortgage loans, net agricultural mortgage loans and residential mortgage loans) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.

Statistical sales information

- Group Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year

premiums and fees from recurring premium policy sales of all products.

- RIS: calculated using 10% of single premium contracts, on and off-balance sheet deposits, and the contract value for new UK longevity reinsurance contracts, and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance.
- Asia, Latin America and EMEA: calculated using 10% of single premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group).

Sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.

The following additional information is relevant to an understanding of MetLife's performance:

- Volume growth, where cited, represents the change in certain measures of our segment results, including adjusted earnings, attributable to business growth, applying a model in which certain margins and factors are held constant, the most significant of which are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates.
- PRT includes U.K. funded reinsurance.
- Holding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short-term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.
- MetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife's holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.
- Notable items reflect the unexpected impact of events that affect MetLife's results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife's results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.
- We refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.

Forward-Looking Statements

This news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as "anticipate," "are confident," "assume,"

“believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. By their nature, forward-looking statements: speak only as of the date they are made; are not statements of historical fact or guarantees of future performance; and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

Many factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:

- (1) economic condition difficulties, including risks relating to interest rates, the effects of announced or future tariff increases on the global economy, credit spreads, declining equity or debt markets, real estate, obligors and counterparties, government default or shutdown, currency exchange rates, derivatives, climate change, public health, terrorism and security;
- (2) global capital and credit market adversity;
- (3) credit facility inaccessibility;
- (4) financial strength or credit ratings downgrades;
- (5) unavailability, unaffordability, or inadequate reinsurance, including reinsurance risks that arise from reinsurers’ credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;
- (6) statutory life insurance reserve financing costs or limited market capacity;
- (7) legal, regulatory, and supervisory and enforcement policy changes;
- (8) changes in tax rates, tax laws or interpretations;
- (9) litigation and regulatory investigations;
- (10) unsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;
- (11) MetLife, Inc.’s inability to pay dividends and repurchase common stock;
- (12) MetLife, Inc.’s subsidiaries’ inability to pay dividends to MetLife, Inc.;
- (13) investment defaults, downgrades, or volatility;
- (14) investment sales or lending difficulties;
- (15) collateral or derivative-related payments;
- (16) investment valuations, allowances, or impairments changes;
- (17) claims or other results that differ from our estimates, assumptions, or models;
- (18) global political, legal, or operational risks;
- (19) business competition;
- (20) technological changes;
- (21) catastrophes;
- (22) climate changes or responses to it;
- (23) deficiencies in our closed block;
- (24) goodwill or other asset impairment, or deferred income tax asset allowance;
- (25) impairment of VOBA, value of distribution agreements acquired or value of customer relationships acquired;
- (26) product guarantee volatility, costs, and counterparty risks;
- (27) risk management failures;
- (28) insufficient protection from operational risks;

- (29) failure to protect confidentiality, integrity or availability of systems or data or other cybersecurity or disaster recovery failures;
- (30) accounting standards changes;
- (31) excessive risk-taking;
- (32) marketing and distribution difficulties;
- (33) pension and other postretirement benefit assumption changes;
- (34) inability to protect our intellectual property or avoid infringement claims;
- (35) acquisition, integration, growth, disposition, or reorganization difficulties;
- (36) Brighthouse Financial, Inc. separation risks;
- (37) MetLife, Inc.'s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and
- (38) legal- and corporate governance-related effects on business combinations.

MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

MetLife, Inc.
GAAP Interim Condensed Consolidated Statements of Operations
(In millions)

	For the Three Months Ended September 30,	
	2025	2024
Revenues		
Premiums	\$ 10,555	\$ 10,647
Universal life and investment-type product policy fees	1,247	1,228
Net investment income	6,089	5,227
Other revenues	724	648
Net investment gains (losses)	(325)	(77)
Net derivative gains (losses)	(929)	767
Total revenues	<u>17,361</u>	<u>18,440</u>
Expenses		
Policyholder benefits and claims	10,369	10,597
Policyholder liability remeasurement (gains) losses	(159)	(132)
Market risk benefit remeasurement (gains) losses	(263)	531
Interest credited to policyholder account balances	2,561	2,037
Policyholder dividends	134	150
Amortization of DAC, VOBA and negative VOBA	522	509
Interest expense on debt	271	257
Other expenses, net of capitalization of DAC	2,716	2,497
Total expenses	<u>16,151</u>	<u>16,446</u>
Income (loss) before provision for income tax	1,210	1,994
Provision for income tax expense (benefit)	308	653
Net income (loss)	<u>902</u>	<u>1,341</u>
Less: Net income (loss) attributable to noncontrolling interests	6	(1)
Net income (loss) attributable to MetLife, Inc.	<u>896</u>	<u>1,342</u>
Less: Preferred stock dividends	66	67
Preferred stock redemption premium	12	—
Net income (loss) available to MetLife, Inc.'s common shareholders	<u>\$ 818</u>	<u>\$ 1,275</u>

See footnotes on last page.

MetLife, Inc.
(In millions, except per share data)

	For the Three Months Ended September 30,			
	2025		2024	
	Earnings Per Weighted Average Common Share Diluted (1)		Earnings Per Weighted Average Common Share Diluted (1)	
Reconciliation to Adjusted Earnings Available to Common Shareholders				
Net income (loss) available to MetLife, Inc.'s common shareholders	\$ 818	\$ 1.22	\$ 1,275	\$ 1.81
Adjustments from net income (loss) available to common shareholders to adjusted earnings available to common shareholders:				
Less: Net investment gains (losses)	(325)	(0.49)	(77)	(0.11)
Net derivative gains (losses)	(929)	(1.39)	767	1.09
Market risk benefit remeasurement gains (losses)	263	0.39	(531)	(0.75)
Goodwill impairment	—	—	—	—
Other adjustments to net income (loss)	20	0.04	(65)	(0.09)
Provision for income tax (expense) benefit	223	0.33	(195)	(0.28)
Add: Net income (loss) attributable to noncontrolling interests	6	0.01	(1)	—
Preferred stock redemption premium	12	0.02	—	—
Adjusted earnings available to common shareholders	1,584	2.37	1,375	1.95
Less: Total notable items	18	0.03	16	0.02
Adjusted earnings available to common shareholders, excluding total notable items	<u>\$ 1,566</u>	<u>\$ 2.34</u>	<u>\$ 1,359</u>	<u>\$ 1.93</u>
Adjusted earnings available to common shareholders on a constant currency basis	\$ 1,584	\$ 2.37	\$ 1,376	\$ 1.96
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis	\$ 1,566	\$ 2.34	\$ 1,360	\$ 1.93
Weighted average common shares outstanding - diluted		669.1		703.7

See footnotes on last page.

MetLife, Inc.
(In millions)

	For the Three Months Ended September 30,	
	2025	2024
Premiums, Fees and Other Revenues		
Premiums, fees and other revenues	\$ 12,526	\$ 12,523
Less: Adjustments to premiums, fees and other revenues:		
Asymmetrical and non-economic accounting	78	50
Other adjustments	(15)	(14)
Divested businesses	2	16
Adjusted premiums, fees and other revenues	<u>\$ 12,461</u>	<u>\$ 12,471</u>
Adjusted premiums, fees and other revenues, on a constant currency basis	\$ 12,461	\$ 12,480
Less: PRT	(10)	529
Adjusted premiums, fees and other revenues, excluding PRT, on a constant currency basis	<u>\$ 12,471</u>	<u>\$ 11,951</u>
Net Investment Income		
Net investment income	\$ 6,089	\$ 5,227
Less: Adjustments to net investment income		
Investment hedge adjustments	(100)	(129)
Joint venture adjustments	(8)	66
Unit-linked contract income	580	147
Reinsurance adjustments	177	—
Divested businesses	—	—
Adjusted net investment income	<u>\$ 5,440</u>	<u>\$ 5,143</u>
Revenues and Expenses		
Total revenues	\$ 17,361	\$ 18,440
Less: Adjustments to total revenues:		
Net investment gains (losses)	(325)	(77)
Net derivative gains (losses)	(929)	767
Investment hedge adjustments	(100)	(129)
Asymmetrical and non-economic accounting	78	50
Joint venture adjustments	(8)	66
Unit-linked contract income	580	147
Reinsurance adjustments	177	—
Other adjustments, excluding Unit-linked contract income and Reinsurance adjustments	(15)	(14)
Divested businesses	2	16
Total adjusted revenues	<u>\$ 17,901</u>	<u>\$ 17,614</u>
Total expenses	\$ 16,151	\$ 16,446
Less: Adjustments to total expenses:		
Market risk benefit remeasurement (gains) losses	(263)	531
Goodwill impairment	—	—
Asymmetrical and non-economic accounting	18	72
Market volatility	(49)	(52)
Unit-linked contract costs	578	143
Reinsurance adjustments	135	—
Other adjustments, excluding Unit-linked contract costs and Reinsurance adjustments	2	12
Divested businesses	10	26
Total adjusted expenses	<u>\$ 15,720</u>	<u>\$ 15,714</u>

See footnotes on last page.

MetLife, Inc.
(In millions, except per share and ratio data)

	For the Three Months Ended September 30,	
	2025	2024
Expense Detail and Ratios		
Reconciliation of Capitalization of DAC to Adjusted Capitalization of DAC		
Capitalization of DAC	\$ (852)	\$ (691)
Less: Divested businesses	—	—
Adjusted capitalization of DAC	<u>\$ (852)</u>	<u>\$ (691)</u>
Reconciliation of Other Expenses to Adjusted Other Expenses		
Other expenses	\$ 3,568	\$ 3,188
Less: Reinsurance adjustments	135	—
Less: Other adjustments, excluding Reinsurance adjustments	2	12
Less: Divested businesses	9	17
Adjusted other expenses	<u>\$ 3,422</u>	<u>\$ 3,159</u>
Other Detail and Ratios		
Other expenses, net of capitalization of DAC	\$ 2,716	\$ 2,497
Premiums, fees and other revenues	\$ 12,526	\$ 12,523
Expense ratio	21.7 %	19.9 %
Direct expenses	\$ 1,443	\$ 1,392
Less: Total notable items related to direct expenses	—	—
Direct expenses, excluding total notable items related to direct expenses	<u>\$ 1,443</u>	<u>\$ 1,392</u>
Adjusted other expenses	\$ 3,422	\$ 3,159
Adjusted capitalization of DAC	(852)	(691)
Adjusted other expenses, net of adjusted capitalization of DAC	2,570	2,468
Less: Total notable items related to adjusted other expenses	102	—
Adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses	<u>\$ 2,468</u>	<u>\$ 2,468</u>
Adjusted premiums, fees and other revenues	\$ 12,461	\$ 12,471
Less: PRT	(10)	529
Adjusted premiums, fees and other revenues, excluding PRT	<u>\$ 12,471</u>	<u>\$ 11,942</u>
Direct expense ratio	11.6 %	11.2 %
Direct expense ratio, excluding total notable items related to direct expenses and PRT	11.6 %	11.7 %
Adjusted expense ratio	20.6 %	19.8 %
Adjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT	19.8 %	20.7 %

See footnotes on last page.

MetLife, Inc.
(In millions, except per share data)

Equity Details	September 30,	
	2025	2024
Total MetLife, Inc.'s stockholders' equity	\$ 28,944	\$ 30,885
Less: Preferred stock	2,830	3,818
MetLife, Inc.'s common stockholders' equity	26,114	27,067
Less: Unrealized investment gains (losses), net of related offsets and income tax	(14,667)	(11,239)
Deferred gains (losses) on derivatives, net of income tax	(1,239)	(292)
Future policy benefits discount rate remeasurement gain (losses), net of income tax	6,028	2,004
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax	(83)	4
Defined benefit plans adjustment, net of income tax	(1,390)	(1,371)
Estimated fair value of certain ceded reinsurance-related embedded derivatives, net of income tax	92	—
Total MetLife, Inc.'s adjusted common stockholders' equity	37,373	37,961
Less: Accumulated year-to-date total notable items, net of income tax	18	16
Total MetLife, Inc.'s adjusted common stockholders' equity, excluding total notable items	\$ 37,355	\$ 37,945
Book Value (2)	September 30,	
	2025	2024
Book value per common share	39.52	39.02
Less: Unrealized investment gains (losses), net of related offsets and income tax	(22.20)	(16.20)
Deferred gains (losses) on derivatives, net of income tax	(1.88)	(0.42)
Future policy benefits discount rate remeasurement gain (losses), net of income tax	9.12	2.89
Market risk benefits instrument-specific credit risk remeasurement gains (losses), net of income tax	(0.13)	0.01
Defined benefit plans adjustment, net of income tax	(2.10)	(1.98)
Estimated fair value of certain ceded reinsurance-related embedded derivatives, net of income tax	0.14	—
Adjusted book value per common share	\$ 56.57	\$ 54.72
Common shares outstanding, end of period (3)	660.7	693.7
Return on Equity	For the Three Months Ended	
	September 30, (4)	
	2025	2024
Return on MetLife, Inc.'s:		
Common stockholders' equity	13.1 %	20.2 %
Adjusted return on MetLife, Inc.'s:		
Adjusted common stockholders' equity	16.9 %	14.6 %
Adjusted common stockholders' equity, excluding total notable items	16.7 %	14.4 %
Average Common Stockholders' Equity	For the Three Months Ended	
	September 30,	
	2025	2024
Average common stockholders' equity	\$ 24,991	\$ 25,251
Average adjusted common stockholders' equity	\$ 37,434	\$ 37,673
Average adjusted common stockholders' equity, excluding total notable items	\$ 37,425	\$ 37,665

See footnotes on last page.

MetLife, Inc.
Adjusted Earnings Available to Common Shareholders
(In millions)

	For the Three Months Ended	
	September 30,	
	2025	2024
Group Benefits (5):		
Adjusted earnings available to common shareholders	\$ 455	\$ 373
Less: Total notable items	(2)	(58)
Adjusted earnings available to common shareholders, excluding total notable items	\$ 457	\$ 431
Adjusted premiums, fees and other revenues	\$ 6,306	\$ 6,146
Retirement & Income Solutions (5):		
Adjusted earnings available to common shareholders	\$ 436	\$ 472
Less: Total notable items	13	104
Adjusted earnings available to common shareholders, excluding total notable items	\$ 423	\$ 368
Adjusted premiums, fees and other revenues	\$ 1,186	\$ 1,579
Less: PRT	(10)	529
Adjusted premiums, fees and other revenues, excluding PRT	\$ 1,196	\$ 1,050
Asia:		
Adjusted earnings available to common shareholders	\$ 543	\$ 306
Less: Total notable items	70	(41)
Adjusted earnings available to common shareholders, excluding total notable items	\$ 473	\$ 347
Adjusted earnings available to common shareholders on a constant currency basis	\$ 543	\$ 305
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis	\$ 473	\$ 346
Adjusted premiums, fees and other revenues	\$ 1,717	\$ 1,710
Adjusted premiums, fees and other revenues, on a constant currency basis	\$ 1,717	\$ 1,704
Latin America:		
Adjusted earnings available to common shareholders	\$ 147	\$ 221
Less: Total notable items	(75)	4
Adjusted earnings available to common shareholders, excluding total notable items	\$ 222	\$ 217
Adjusted earnings available to common shareholders on a constant currency basis	\$ 147	\$ 222
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis	\$ 222	\$ 218
Adjusted premiums, fees and other revenues	\$ 1,663	\$ 1,496
Adjusted premiums, fees and other revenues, on a constant currency basis	\$ 1,663	\$ 1,498

See footnotes on last page.

MetLife, Inc.
Adjusted Earnings Available to Common Shareholders (Continued)
(In millions)

	For the Three Months Ended	
	September 30,	
	2025	2024
EMEA:		
Adjusted earnings available to common shareholders	\$ 88	\$ 70
Less: Total notable items	(1)	(5)
Adjusted earnings available to common shareholders, excluding total notable items	<u>\$ 89</u>	<u>\$ 75</u>
Adjusted earnings available to common shareholders on a constant currency basis	\$ 88	\$ 71
Adjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis	\$ 89	\$ 76
Adjusted premiums, fees and other revenues	\$ 727	\$ 655
Adjusted premiums, fees and other revenues, on a constant currency basis	\$ 727	\$ 668
MetLife Holdings (5):		
Adjusted earnings available to common shareholders	\$ 203	\$ 182
Less: Total notable items	13	12
Adjusted earnings available to common shareholders, excluding total notable items	<u>\$ 190</u>	<u>\$ 170</u>
Adjusted premiums, fees and other revenues	\$ 729	\$ 793
Corporate & Other (5):		
Adjusted earnings available to common shareholders	\$ (288)	\$ (249)
Less: Total notable items	—	—
Adjusted earnings available to common shareholders, excluding total notable items	<u>\$ (288)</u>	<u>\$ (249)</u>
Adjusted premiums, fees and other revenues	\$ 133	\$ 92

See footnotes on last page.

	For the Three Months Ended	
	September 30, 2025	September 30, 2025
	Variable Investment Income (post-tax, \$ in millions) (6)	Assets (\$ in billions)
Group Benefits	\$ 5	\$ 0.2
RIS	146	5.6
Asia	139	8.3
Latin America	2	0.3
EMEA	—	—
MetLife Holdings	76	3.4
Corporate & Other	14	1.1
Total	<u>\$ 382</u>	<u>\$ 18.9</u>

Segments: Group Benefits, RIS, Asia, Latin America and EMEA (7)

	Capital Deployed	Value of New Business	Internal Rate of Return	Payback (Years)
Value of new business (\$ in billions)				
2024	\$ 3.4	\$ 2.6	19 %	5
2023	\$ 3.6	\$ 2.6	19 %	5
2022	\$ 3.7	\$ 2.3	17 %	6
2021	\$ 2.8	\$ 1.9	17 %	6
2020	\$ 3.2	\$ 1.9	17 %	6

See footnotes on last page.

MetLife, Inc.

Cash & Capital (8), (9), (in billions)	September 30, 2025
Holding Companies Cash & Liquid Assets	\$ 4.9

Footnotes

- (1) Adjusted earnings available to common shareholders, excluding total notable items, per diluted common share is calculated on a standalone basis and may not equal (i) adjusted earnings available to common shareholders per diluted common share, less (ii) total notable items per diluted common share.
- (2) Book values exclude \$2,830 million and \$3,818 million of equity related to preferred stock at September 30, 2025 and September 30, 2024, respectively.
- (3) There were share repurchases of \$502 million for the three months ended September 30, 2025. Year-to-date, there were share repurchases of approximately \$2.6 billion, including approximately \$150 million of share repurchases in October 2025. Common stock dividends totaling \$378 million were paid for the three months ended September 30, 2025.
- (4) Annualized using quarter-to-date results.
- (5) Results on a constant currency basis are not included as constant currency impact is not significant.
- (6) Assumes a 21% tax rate.
- (7) Excludes MetLife Holdings; Value of New Business is the present value of future profits net of the cost of capital and time value of guarantees from new sales.
- (8) The total U.S. statutory adjusted capital, on a National Association of Insurance Commissioners basis, is expected to be approximately \$17.1 billion at September 30, 2025, flat from \$17.1 billion at June 30, 2025. This balance includes MetLife, Inc.'s principal U.S. insurance subsidiaries, excluding American Life Insurance Company.
- (9) The expected Japan solvency margin ratio as of September 30, 2025 is approximately 740%.